Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
The Board of Control for Cricket in India (BCCI) has made a bold and significant…
Madhya Pradesh, a state rich in culture and traditions, celebrates many colorful festivals. One of…
The Ustad Bismillah Khan Yuva Puraskar (UBKUP) is a prestigious award instituted by the Sangeet…
The Sustainable Trade Index 2024, jointly published by the Hinrich Foundation and IMD, highlights the…
The title "Frontier Gandhi" refers to Khan Abdul Ghaffar Khan, a prominent leader from British…
India will host the International Cooperative Alliance (ICA) Global Cooperative Conference in New Delhi from…